# Mechanistic insights into triclosan-induced hepatotoxicity: A network toxicology and molecular docking approach

**Authors:** Fuzhi Liu, Yanyan Zhao, Dandan Zhu, Jingwen Wang, Zhaocheng Zhuang, Yangjia Chen, Yuan Su, Zhuote Tu, Yanggang Hong, Ch Ratnasekhar, Ch Ratnasekhar

PMC · DOI: 10.1371/journal.pone.0333244 · PLOS One · 2026-02-25

## TL;DR

This study explores how triclosan, an antimicrobial chemical, causes liver damage by identifying key targets and pathways involved in its toxic effects.

## Contribution

The study introduces a new approach combining network toxicology and molecular docking to evaluate health risks of environmental pollutants like triclosan.

## Key findings

- Triclosan's liver toxicity is linked to six key targets including TP53, EGFR, and AKT1.
- Five critical pathways such as cancer activation and endocrine resistance are involved in triclosan-induced liver damage.
- Molecular docking confirmed strong binding of triclosan to core targets with binding energy less than −5.5 kcal/mol.

## Abstract

Triclosan (TCS) is an artificially synthesized broad-spectrum antimicrobial agent, which is widely used in personal care products. It is a new endocrine disruptor and has potential health hazards to human body.

Based on network toxicology and molecular docking technology, the compounds that may cause hepatotoxicity in triclosan were predicted and the mechanism was discussed.

From April to May 2025, the targets of triclosan were identified using databases such as STITCH, CTD, Swiss Target Prediction, and TargetNet. Additionally, gene targets associated with liver toxicity were identified from the GeneCards and OMIM databases. The intersection of triclosan-targets and liver toxicity-related gene targets was used to identify candidate targets. Using the String platform, a protein interaction network was constructed for these candidate targets to identify core functional modules within the network. The candidate targets were analyzed for GO and KEGG enrichment using DAVID, and a triclosan-liver toxicity-target pathway network was constructed using Cytoscape 3.10.1 software. Network topology analysis was conducted to screen for key components and targets. Finally, molecular docking was performed on the core targets using CB-Dock2.

683 candidate targets for liver toxicity caused by triclosan were identified. The core targets for liver toxicity from triclosan production include TP53, EGFR, AKT1, IL6, JUN, and FN1. Molecular docking analysis shows that the binding free energy of triclosan with these core targets is less than −5.5 kcal/mol. The comprehensive analysis results showed that the liver damage caused by triclosan was mainly related to the activation of Pathways in cancer, Endocrine resistance, AGE-RAGE signaling pathway in diabetic complications, hepatitis B, and lipid and atherosclerosis signaling pathways.

The potential targets and molecular mechanisms of triclosan (TCS) induced liver injury were investigated, and 6 key targets and 5 pathways were identified, providing a new paradigm for evaluating the health risks caused by environmental pollutants.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], IL6 (interleukin 6) [NCBI Gene 3569], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725], FN1 (fibronectin 1) [NCBI Gene 2335]
- **Chemicals:** triclosan (PubChem CID 5564), TCS (PubChem CID 5564)

## Full-text entities

- **Genes:** EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, MAP3K7 (mitogen-activated protein kinase kinase kinase 7) [NCBI Gene 6885] {aka CSCF, FMD2, MEKK7, TAK1, TGF1a}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, USP1 (ubiquitin specific peptidase 1) [NCBI Gene 7398] {aka UBP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TRAF3IP2 (TRAF3 interacting protein 2) [NCBI Gene 10758] {aka ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CANDF8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, DCTN6 (dynactin subunit 6) [NCBI Gene 10671] {aka WS-3, WS3, p27}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BRD4 (bromodomain containing 4) [NCBI Gene 23476] {aka CAP, CDLS6, FSHRG4, HUNK1, HUNKI, MCAP}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, pparab (peroxisome proliferator-activated receptor alpha b) [NCBI Gene 557714] {aka PPAR[a], ppara, ppara1, pparal}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, GRB2 (growth factor receptor bound protein 2) [NCBI Gene 2885] {aka ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2}, dre-mir-30b (microRNA 30b) [NCBI Gene 100033610] {aka mir30b}, DOCK2 (dedicator of cytokinesis 2) [NCBI Gene 1794] {aka IMD40}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, myd88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 403145] {aka zgc:103541}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, tp53 (tumor protein p53) [NCBI Gene 30590] {aka brp53, drp53, etID22686.5, fb40d06, p53, wu:fb40d06}, nfe2l2a (nfe2 like bZIP transcription factor 2a) [NCBI Gene 360149] {aka Nrf2, nfe2l2, wu:fc15g09, wu:fj67e03}, pparaa (peroxisome proliferator-activated receptor alpha a) [NCBI Gene 563298] {aka ppara3, si:ch211-239e6.3}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, traf6 (TNF receptor-associated factor 6) [NCBI Gene 554561] {aka fi15f02, wu:fi15f02, zgc:63704}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}
- **Diseases:** metabolic dysregulation (MESH:D021081), metabolic dysfunction (MESH:D008659), Inheritance (MESH:D030342), carcinogenesis (MESH:D063646), noncommunicable diseases (MESH:D000073296), Hepatitis B (MESH:D006509), liver fibrosis (MESH:D008103), diabetes (MESH:D003920), cancer (MESH:D009369), behavioral abnormalities (MESH:D001523), Non-alcoholic fatty liver disease (MESH:D065626), fibrosis (MESH:D005355), Chronic inflammation (MESH:D007249), fatty (MESH:D008067), intestinal toxicity (MESH:D007410), impaired fertility and development (MESH:D002658), necrosis (MESH:D009336), hepatocellular carcinoma (MESH:D006528), liver dysfunction (MESH:D017093), hepatic toxicity (MESH:D056486), toxicity (MESH:D064420), COVID-19 (MESH:D000086382), Endocrine (MESH:D004700), atherosclerosis (MESH:D050197), Amoebiasis (MESH:D000562), carcinogenic (MESH:D011230), hepatic lipid metabolism disorders (MESH:D052439), diabetic complications (MESH:D048909), metastasis (MESH:D009362)
- **Chemicals:** aniline (MESH:C023650), water (MESH:D014867), reactive oxygen species (MESH:D017382), hydrogen (MESH:D006859), TCS (MESH:D014260), LPS (MESH:D008070), chloroform (MESH:D002725), Lipid (MESH:D008055), oils (MESH:D009821), dioxins (MESH:D004147), -D-25-48366 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Cell lines:** HepaRG — Homo sapiens (Human), Hepatitis C infection, Cancer cell line (CVCL_9720)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935200/full.md

## Figures

17 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935200/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935200/full.md

---
Source: https://tomesphere.com/paper/PMC12935200